Overview

* Cumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last year

* Company reports Q3 net loss of $1.9 mln

* Cumberland partners with RedHill to commercialize Talicia, expanding product portfolio

Outlook

* Company did not provide specific financial guidance for future quarters

Result Drivers

* PRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolio

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $8.30

Revenue mln

Q3 -$0.06

Adjusted

EPS

Q3 Net -$1.9

Income mln

Q3 $10.3

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)